Reviews Trasylol


No reviews yet.

Trasylol Drug Description
TRASYLOL®
(aprotinin injection)

Trasylol® administration
may cause fatal anaphylactic or anaphylactoid reactions. Fatal reactions have
occurred with an initial (test) dose as well as with any of the components of
the dose regimen. Fatal reactions have also occurred in situations where the
initial (test) dose was tolerated. The risk for anaphylactic or anaphylactoid
reactions is increased among patients with prior aprotinin exposure and a history
of any prior aprotinin exposure must be sought prior to Trasylol®
administration. The risk for a fatal reaction appears to be greater upon re-exposure
within 12 months of the most recent prior aprotinin exposure. Trasylol®
should be administered only in operative settings where cardiopulmonary bypass
can be rapidly initiated. The benefit of Trasylol®
to patients undergoing primary CABG surgery should be weighed against the risk
of anaphylaxis associated with any subsequent exposure to aprotinin. (See CONTRAINDICATIONS,
WARNINGS and PRECAUTIONS).


DRUG DESCRIPTION
Trasylol® (aprotinin injection), C284H432N84O79S7, is a natural proteinase inhibitor obtained from bovine lung. Aprotinin (molecular weight of 6512 daltons), consists of 58 amino acid residues that are arranged in a single polypeptide chain, cross-linked by three disulfide bridges. It is supplied as a clear, colorless, sterile isotonic solution for intravenous administration. Each milliliter contains 10,000 KIU (Kallikrein Inhibitor Units) (1.4 mg/mL) and 9 mg sodium chloride in water for injection. Hydrochloric acid and/or sodium hydroxide is used to adjust the pH to 4.5-6.5.


Last reviewed on RxList: 3/16/2007




Trasylol Drug Description
TRASYLOL®
(aprotinin injection)

Trasylol® administration
may cause fatal anaphylactic or anaphylactoid reactions. Fatal reactions have
occurred with an initial (test) dose as well as with any of the components of
the dose regimen. Fatal reactions have also occurred in situations where the
initial (test) dose was tolerated. The risk for anaphylactic or anaphylactoid
reactions is increased among patients with prior aprotinin exposure and a history
of any prior aprotinin exposure must be sought prior to Trasylol®
administration. The risk for a fatal reaction appears to be greater upon re-exposure
within 12 months of the most recent prior aprotinin exposure. Trasylol®
should be administered only in operative settings where cardiopulmonary bypass
can be rapidly initiated. The benefit of Trasylol®
to patients undergoing primary CABG surgery should be weighed against the risk
of anaphylaxis associated with any subsequent exposure to aprotinin. (See CONTRAINDICATIONS,
WARNINGS and PRECAUTIONS).


DRUG DESCRIPTION
Trasylol® (aprotinin injection), C284H432N84O79S7, is a natural proteinase inhibitor obtained from bovine lung. Aprotinin (molecular weight of 6512 daltons), consists of 58 amino acid residues that are arranged in a single polypeptide chain, cross-linked by three disulfide bridges. It is supplied as a clear, colorless, sterile isotonic solution for intravenous administration. Each milliliter contains 10,000 KIU (Kallikrein Inhibitor Units) (1.4 mg/mL) and 9 mg sodium chloride in water for injection. Hydrochloric acid and/or sodium hydroxide is used to adjust the pH to 4.5-6.5.


Last reviewed on RxList: 3/16/2007




Trasylol Drug Description
TRASYLOL®
(aprotinin injection)

Trasylol® administration
may cause fatal anaphylactic or anaphylactoid reactions. Fatal reactions have
occurred with an initial (test) dose as well as with any of the components of
the dose regimen. Fatal reactions have also occurred in situations where the
initial (test) dose was tolerated. The risk for anaphylactic or anaphylactoid
reactions is increased among patients with prior aprotinin exposure and a history
of any prior aprotinin exposure must be sought prior to Trasylol®
administration. The risk for a fatal reaction appears to be greater upon re-exposure
within 12 months of the most recent prior aprotinin exposure. Trasylol®
should be administered only in operative settings where cardiopulmonary bypass
can be rapidly initiated. The benefit of Trasylol®
to patients undergoing primary CABG surgery should be weighed against the risk
of anaphylaxis associated with any subsequent exposure to aprotinin. (See CONTRAINDICATIONS,
WARNINGS and PRECAUTIONS).


DRUG DESCRIPTION
Trasylol® (aprotinin injection), C284H432N84O79S7, is a natural proteinase inhibitor obtained from bovine lung. Aprotinin (molecular weight of 6512 daltons), consists of 58 amino acid residues that are arranged in a single polypeptide chain, cross-linked by three disulfide bridges. It is supplied as a clear, colorless, sterile isotonic solution for intravenous administration. Each milliliter contains 10,000 KIU (Kallikrein Inhibitor Units) (1.4 mg/mL) and 9 mg sodium chloride in water for injection. Hydrochloric acid and/or sodium hydroxide is used to adjust the pH to 4.5-6.5.


Last reviewed on RxList: 3/16/2007




Trasylol Drug Description
TRASYLOL®
(aprotinin injection)

Trasylol® administration
may cause fatal anaphylactic or anaphylactoid reactions. Fatal reactions have
occurred with an initial (test) dose as well as with any of the components of
the dose regimen. Fatal reactions have also occurred in situations where the
initial (test) dose was tolerated. The risk for anaphylactic or anaphylactoid
reactions is increased among patients with prior aprotinin exposure and a history
of any prior aprotinin exposure must be sought prior to Trasylol®
administration. The risk for a fatal reaction appears to be greater upon re-exposure
within 12 months of the most recent prior aprotinin exposure. Trasylol®
should be administered only in operative settings where cardiopulmonary bypass
can be rapidly initiated. The benefit of Trasylol®
to patients undergoing primary CABG surgery should be weighed against the risk
of anaphylaxis associated with any subsequent exposure to aprotinin. (See CONTRAINDICATIONS,
WARNINGS and PRECAUTIONS).


DRUG DESCRIPTION
Trasylol® (aprotinin injection), C284H432N84O79S7, is a natural proteinase inhibitor obtained from bovine lung. Aprotinin (molecular weight of 6512 daltons), consists of 58 amino acid residues that are arranged in a single polypeptide chain, cross-linked by three disulfide bridges. It is supplied as a clear, colorless, sterile isotonic solution for intravenous administration. Each milliliter contains 10,000 KIU (Kallikrein Inhibitor Units) (1.4 mg/mL) and 9 mg sodium chloride in water for injection. Hydrochloric acid and/or sodium hydroxide is used to adjust the pH to 4.5-6.5.


Last reviewed on RxList: 3/16/2007




Trasylol Drug Description
TRASYLOL®
(aprotinin injection)

Trasylol® administration
may cause fatal anaphylactic or anaphylactoid reactions. Fatal reactions have
occurred with an initial (test) dose as well as with any of the components of
the dose regimen. Fatal reactions have also occurred in situations where the
initial (test) dose was tolerated. The risk for anaphylactic or anaphylactoid
reactions is increased among patients with prior aprotinin exposure and a history
of any prior aprotinin exposure must be sought prior to Trasylol®
administration. The risk for a fatal reaction appears to be greater upon re-exposure
within 12 months of the most recent prior aprotinin exposure. Trasylol®
should be administered only in operative settings where cardiopulmonary bypass
can be rapidly initiated. The benefit of Trasylol®
to patients undergoing primary CABG surgery should be weighed against the risk
of anaphylaxis associated with any subsequent exposure to aprotinin. (See CONTRAINDICATIONS,
WARNINGS and PRECAUTIONS).


DRUG DESCRIPTION
Trasylol® (aprotinin injection), C284H432N84O79S7, is a natural proteinase inhibitor obtained from bovine lung. Aprotinin (molecular weight of 6512 daltons), consists of 58 amino acid residues that are arranged in a single polypeptide chain, cross-linked by three disulfide bridges. It is supplied as a clear, colorless, sterile isotonic solution for intravenous administration. Each milliliter contains 10,000 KIU (Kallikrein Inhibitor Units) (1.4 mg/mL) and 9 mg sodium chloride in water for injection. Hydrochloric acid and/or sodium hydroxide is used to adjust the pH to 4.5-6.5.


Last reviewed on RxList: 3/16/2007





Other reviews about Trasylol on wordpress

Trasylol Heart Surgery Side Effects
  by Lawyers Attorneys
In 1993, Trasylol (generically known as “aprotinin”) received FDA approval for use in certain cardiac surgeries. Trasylol is still used today to reduce the amount […]


Trasylol Kidney Failure
  by Lawyers Attorneys
A recent study based on observations at 69 leading cardiac centers around the world was published regarding Bayer Pharmaceutical's heart surgery drug Trasylol. Kidney failure, heart failure, and […]


FDA- MedWatch- Aprotinin Injection (marketed as Trasylol)- Patient Enrollment In The Aprotinin Treatment Group Arm of BART Study Stopped
  by 22sfsf23
MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramFDA informed healthcare professionals of the Data Safety MonitoringBoard's recommendation to stop patient enrollment in the aprotinintreatment group […]


BAYER WITHDRAWS ANTIBLEEDING DRUG TRASYLOL
  by Sandy G.
Study finds drug carries increased risk of deathBayer has announced it is suspending sales of Trasylol worldwide amid evidence that the antibleeding drug may have a higher risk […]


Trasylol (aprotinin injection)
  by MarkS
FDA announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol (aprotinin injection), a drug used to control bleeding during […]


Bayer AG and 60 Minutes and Trasylol
  by Jon Lewis
Cory Watson Crowder & DeGaris has filed numerous lawsuits over the drug Trasylol.  The drug is manufactured by Bayer AG, and it is used to prevent excessive bleeding […]


Trasylol risks
  by Dave Austin
Heart surgery patients were more likely to die if given an antibleeding drug, Trasylol, two new studies have found.The manufacturer, Bayer, stopped selling the drug after a Canadian […]


Dying Risk Increased with Heart Drug
  by Dave Austin
A Canadian study reported in The New England Journal of Medicine indicates that patients who were given aprontin during heart surgery were more likely to die from complications […]


Another Study Warns of Risk From Cardiac Surgery Drug
  by timeinctemp
TUESDAY, Dec. 2 (HealthDay News) — A new study casts more doubt on the safety of the drug Trasylol (aprotinin), used to limit bleeding in patients undergoing surgery. Trasylol […]


Trasylol Attorneys Take Note on The True Effects of the Drug
  by braininjuryhna
Trasylol, manufactured by Bayer Pharmaceuticals was one of the most common drugs used during heart bypass surgeries for the last 14 years. However in 2007, the FDA recalled […]



Other reviews about Trasylol on web:

Official pharmaceutical website intended for health professionals. The Official Trasylol Aprotinin Injection by Bayer Pharmaceuticals ...


The drug aprotinin (Trasylol, Bayer), is the bovine version of the small protein basic pancreatic trypsin inhibitor, or BPTI, which inhibits trypsin and related proteolytic ... Aprotinin - Wikipedia, the free encyclopedia


Learn about the prescription medication Trasylol (Aprotinin), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Trasylol (Aprotinin) Drug Information: Uses, Side Effects, Drug ...


Manufactured by Bayer, Trasylol was used to reduce bleeding during complicated surgeries. However, the drug was temporarily withdrawn worldwide in 2007 after studies suggested that ... Trasylol Recall | Beasley Allen


60 Minutes on CBS News: One Thousand Lives A Month - Researcher Estimates 22,000 Lives Could Have Been Saved Had Trasylol Been Pulled Earlier One Thousand Lives A Month - 60 Minutes - CBS News


Accurate, FDA approved Trasylol information for healthcare professionals and patients - brought to you by Drugs.com. Trasylol Official FDA information, side effects and uses.


Trasylol side effects and Trasylol lawsuit information. For more information regarding an individual or Trasylol class action lawsuit or for a free case evaluation from one of ... Trasylol Lawyer - Trasylol Side Effects - Trasylol Lawsuit - Class ...


Learn about the Trasylol FDA recall and the dangerous side effects of the drug, which include risk of kidney problems, heart attacks, and strokes. Trasylol has already caused over ... Trasylol FDA Recall: Side Effects, Injury and Death – Class ...


All about Trasylol. View complete and up to date Trasylol information - part of the Drugs.com trusted medication database. Trasylol Facts and Comparisons at Drugs.com


FDA says clotting drug poses increased death risk, while company says drug still has benefits Trasylol Pulled From Worldwide Market





Featured Reviews

Reviews Thalidomide

Thalomid Drug Description THALOMID® (thalidomide) Capsules 50 mg, 100 mg, 150 mg & 200 mg WARNING SEVERE, LIFE-THREATENING HUMAN BIRTH DEFECTS. IF THALIDOMIDE IS TAKEN DURING PREGNANCY, IT CAN CAUSE SEVERE BIRTH DEFECTS ...
Read More  |  Review This
Reviews Catapres

Catapres Drug Description Catapres (clonidine hydrochloride, USP) Oral Antihypertensive Tablets of 0.1, 0.2 and 0.3 mg DRUG DESCRIPTION What are the possible side effects of clonidine (Catapres)? Get emergency medical help...
Read More  |  Review This
Reviews Valproic Acid

Stavzor Drug Description Stavzor (valproic acid) Delayed Release Capsules WARNING: LIFE-THREATENING ADVERSE REACTIONS Hepatotoxicity Hepatic failure resulting in fatalities has occurred in patients receiving valproic acid and its...
Read More  |  Review This
Reviews Pancrelipase Delayed-Released Capsules

Creon 10 Drug Description CREON® 10 MINIMICROSPHERES® (pancrelipase) Delayed-release Capsules, USP DRUG DESCRIPTION What are the possible side effects of pancrelipase? Get emergency medical help if you have any of these...
Read More  |  Review This
Reviews Amino Acid Injection 5% in 25% Dextrose Injection

Aminosyn II 5% in 25% Dextrose Drug Description AMINOSYN® II 5% in 25% Dextrose Injection AN AMINO ACID INJECTION IN DEXTROSE INJECTION NOTE: These solutions are hypertonic. See WARNINGS and PRECAUTIONS. Nutrimix® Dual-chamber...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....